Rep. Maria Elvira Salazar Unloads Shares of Moderna, Inc. (NASDAQ:MRNA)

Posted by Brenda Bartman on Oct 10th, 2026

Representative Maria Elvira Salazar (Republican-Florida) recently sold shares of Moderna, Inc. (NASDAQ:MRNA). In a filing disclosed on October 7th, the Representative disclosed that they had sold between $1,001 and $15,000 in Moderna stock on September 24th. The trade occurred in the Representative’s “UBS IRA ACCOUNT” account.

Representative Maria Elvira Salazar also recently made the following trade(s):

Sold $1,001 – $15,000 in shares of Citigroup (NYSE:C) on 9/24/2026.
Sold $1,001 – $15,000 in shares of Chubb (NYSE:CB) on 9/24/2026.
Sold $1,001 – $15,000 in shares of Microsoft (NASDAQ:MSFT) on 9/24/2026.
Sold $1,001 – $15,000 in shares of GE Aerospace (NYSE:GE) on 9/24/2026.
Sold $1,001 – $15,000 in shares of Honeywell International (NASDAQ:HON) on 9/24/2026.
Sold $1,001 – $15,000 in shares of Snowflake (NYSE:SNOW) on 9/24/2026.
Sold $1,001 – $15,000 in shares of FedEx (NYSE:FDX) on 9/24/2026.
Sold $1,001 – $15,000 in shares of Salesforce (NYSE:CRM) on 9/24/2026.
Sold $1,001 – $15,000 in shares of RH (NYSE:RH) on 9/24/2026.
Sold $1,001 – $15,000 in shares of Meta Platforms (NASDAQ:META) on 9/24/2026.

Moderna Price Performance

Shares of NASDAQ MRNA opened at $225.00 on Friday. The firm has a market cap of $89.83 billion, a P/E ratio of -28.16 and a beta of 1.09. Moderna, Inc. has a twelve month low of $22.28 and a twelve month high of $225.00. The company has a quick ratio of 2.18, a current ratio of 2.29 and a debt-to-equity ratio of 0.09. The company has a 50 day moving average of $140.07 and a 200 day moving average of $84.92.

Moderna (NASDAQ:MRNA – Get Free Report) last posted its earnings results on Friday, July 31st. The company reported ($1.97) EPS for the quarter, topping analysts’ consensus estimates of ($2.03) by $0.06. The business had revenue of $145.00 million during the quarter, compared to analyst estimates of $102.93 million. Moderna had a negative return on equity of 28.30% and a negative net margin of 141.43%. The company’s quarterly revenue was up 2.1% compared to the same quarter last year. During the same quarter last year, the company earned ($2.13) EPS. As a group, research analysts expect that Moderna, Inc. will post -6.11 EPS for the current fiscal year.

Insider Buying and Selling at Moderna

In related news, CFO James M. Mock sold 34,836 shares of the stock in a transaction dated Thursday, September 10th. The shares were sold at an average price of $134.49, for a total value of $4,685,093.64. Following the completion of the transaction, the chief financial officer owned 59,375 shares of the company’s stock, valued at approximately $7,985,343.75. This trade represents a 36.98% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, President Stephen Hoge sold 40,294 shares of the business’s stock in a transaction that occurred on Monday, September 14th. The stock was sold at an average price of $144.13, for a total value of $5,807,574.22. Following the sale, the president directly owned 1,525,858 shares in the company, valued at $219,921,913.54. The trade was a 2.57% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold 118,882 shares of company stock worth $16,862,280 over the last 90 days. 10.80% of the stock is owned by insiders.

Hedge Funds Weigh In On Moderna

Several large investors have recently made changes to their positions in the business. BlackRock Inc. purchased a new stake in shares of Moderna in the second quarter worth about $2,142,877,000. Capital World Investors bought a new position in shares of Moderna during the 4th quarter valued at approximately $378,299,000. Theleme Partners LLP bought a new position in shares of Moderna during the 2nd quarter valued at approximately $564,272,000. Merck & Co. Inc. purchased a new position in shares of Moderna in the second quarter valued at $161,642,545. Finally, Bamco Inc. NY bought a new stake in Moderna in the second quarter worth $139,317,000. 75.33% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Ratings Changes

MRNA has been the subject of a number of recent analyst reports. William Blair initiated coverage on Moderna in a research report on Friday, August 28th. They issued an “outperform” rating for the company. Jefferies Financial Group reiterated a “hold” rating on shares of Moderna in a research note on Wednesday, August 19th. Morgan Stanley boosted their target price on shares of Moderna from $89.00 to $95.00 and gave the company an “equal weight” rating in a research note on Wednesday. Royal Bank Of Canada restated a “sector perform” rating and issued a $130.00 price target on shares of Moderna in a research note on Wednesday, August 19th. Finally, Loop Capital set a $135.00 price objective on Moderna in a research report on Wednesday, August 19th. Seven analysts have rated the stock with a Buy rating, thirteen have given a Hold rating and five have issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company has an average rating of “Hold” and a consensus price target of $78.17.

View Our Latest Report on Moderna

Moderna News Summary

Here are the key news stories impacting Moderna this week:

Positive Sentiment: Cancer-vaccine initiative drives investor enthusiasm: Reports that the NIH plans to expedite cancer-vaccine development, along with details of a planned national effort, led investors to view Moderna as a major potential beneficiary because of its mRNA platform and oncology ambitions. Moderna stock jumps on planned national cancer vaccine effort
Positive Sentiment: Nasdaq-100 inclusion supports demand: Moderna rejoined the Nasdaq-100, replacing Warner Bros. Discovery. The change may prompt buying by index-tracking funds and increases the company’s visibility with institutional investors after its substantial long-term share-price recovery. Moderna returns to the Nasdaq-100
Positive Sentiment: Broad biotech rally adds momentum: Vaccine and biotechnology stocks rose broadly, with Moderna among the prominent gainers. Sector-wide strength likely amplified the company-specific rally. Biotech stocks rally
Neutral Sentiment: Pipeline narrative is expanding beyond COVID-19: Coverage highlighted Moderna’s development of flu vaccines and cancer therapies, reinforcing the company’s strategy to build additional commercial franchises. However, these programs remain dependent on clinical, regulatory and commercial execution. The science and politics of the new mRNA flu vaccine
Negative Sentiment: Valuation and execution concerns remain: Morgan Stanley maintained a Hold rating, while reports emphasized the challenge of manufacturing a potential cancer franchise at scale. These issues could limit further gains if clinical progress does not translate into sales and profits. Moderna gets a Hold from Morgan Stanley
Negative Sentiment: Insider selling is a cautionary signal: Coverage noted that insiders have trimmed holdings as the stock has surged, potentially signaling profit-taking or caution after the steep rally. Moderna insiders trim holdings

About Representative Salazar

Maria Elvira Salazar (Republican Party) is a member of the U.S. House, representing Florida’s 27th Congressional District. She assumed office on January 3, 2021. Her current term ends on January 3, 2027.

Salazar (Republican Party) ran for re-election to the U.S. House to represent Florida’s 27th Congressional District. She won in the general election on November 5, 2024.

Maria Elvira Salazar was born in Miami, Florida, and lives in Coral Gables, Florida. Salazar earned an undergraduate degree from the University of Miami in 1983 and a graduate degree from Harvard University in 1995. Her career experience includes working as a television journalist, reporter, and news anchor.

About Moderna

(Get Free Report)

Moderna, Inc is a biotechnology company that develops medicines and vaccines using messenger RNA (mRNA) technology. Its platform is designed to instruct cells to produce proteins that can help prevent or treat disease, supporting the company’s work across infectious diseases, immuno-oncology, rare diseases, autoimmune conditions, and cardiovascular diseases.

Moderna’s commercial products include Spikevax, an mRNA vaccine for COVID-19, and mRESVIA, an mRNA vaccine for respiratory syncytial virus (RSV) in older adults.